- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT02113878
Badanie fazy Ib BKM120 z cisplatyną i XRT w miejscowo zaawansowanym raku płaskonabłonkowym głowy i szyi wysokiego ryzyka
Badanie fazy Ib BKM120 z cotygodniową cisplatyną i radioterapią w miejscowo zaawansowanym raku płaskonabłonkowym głowy i szyi wysokiego ryzyka
This research study is evaluating a drug called buparlisib (BKM120) as a possible treatment for locally advanced head and neck squamous cell cancer.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
- This phase Ib study is combining standard chemoradiotherapy with weekly cisplatin and BKM120 to assess tolerability of this combination in high risk patients with locally advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN). The investigators will also obtain preliminary information about the efficacy of this treatment.
- The participant will receive the study drug buparlisib once daily, by mouth, for 45 days. The participant will be given a study drug-dosing diary for each cycle. It will include special instructions for taking the study drug at home.
- The investigators are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study before and how well they have tolerated their doses.
- All participants will receive weekly cisplatin injection. Cisplatin will be given intra-venously (IV) on days: (1, 8, 15, 22, 29, 36 and 43) at DFCI.
- All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks, delivered at DFCI. IMRT is a type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor.
- The investigators would like to keep track of the participant's medical condition. Follow-up will continue every 4 to 12 weeks after the end of treatment for the first year and at the investigator's discretion thereafter.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02115
- Dana-Farber Cancer Institute
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Stage III/IV, locally advanced, biopsy proven squamous cell cancer of the head and neck that undergo chemoradiation as their primary treatment with curative intent.
- Oropharynx (HPV positive and HPV negative), hypopharynx, larynx primaries, nasopharynx as well as those with documented SCC of the cervical lymph nodes, with unknown primaries.
- >10 pack years of tobacco use
- Age ≥ 18 years
- ECOG performance status ≤ 2
- At least one site of measurable disease
- Adequate bone marrow function as shown by: ANC > 1.5 x 109/L, Platelets >100 x 109/L, Hb >9 g/dL
- Total calcium (corrected for serum albumin) within normal limits
- Magnesium ≥ the lower limit of normal
- Potassium within normal limits for the institution.
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range
- Serum bilirubin within normal range (or ≤ 1.5 x ULN if liver metastases are present; or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert Syndrome)
- Serum creatinine ≤ 1.5 x ULN or 24-hour clearance ≥ 50 mL/min
- Serum amylase ≤ ULN
- Serum lipase ≤ ULN
- Fasting plasma glucose ≤ 120 mg/dL (6.7 mmol/L)
- Signed informed consent
- INR ≤ 2
Exclusion Criteria:
- Distant metastatic disease
- Less than or equal to 10 pack years of tobacco history
- Received prior chemotherapy
- Received prior radiation to the head and neck or adjacent anatomical site
- Received prior treatment with a P13K inhibitor.
- Known hypersensitivity to BKM120 or to its excipients
- Acute or chronic liver, renal disease or pancreatitis
- Mood disorders ≥ CTCAE grade 3
- Diarrhea ≥ CTCAE grade 2
- Active cardiac disease
- History of cardiac dysfunction including any of the following:
- Patient has poorly
- Impairment of gastrointestinal (GI) function
- Currently receiving treatment with medication with a known risk to prolong the QT interval or inducing Torsades de Pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug.
- Chronic treatment with steroids or another immunosuppressive agent.
- Herbal medications and certain fruits within 7 days prior to starting study drug.
- Currently treated with drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A, and the treatment cannot be discontinued or switched to a different medication prior to starting study drug. Please refer to Appendix B for a list of prohibited inhibitors and inducers of CYP3A (Please note that co-treatment with weak inhibitors of CYP3A is allowed).
- Undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy.
- Currently taking therapeutic doses of warfarin sodium or any other coumadin-derivative anticoagulant.
- Women who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control.
- Known diagnosis of human immunodeficiency virus (HIV) infection
- History of another malignancy within 3 years, except cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nielosowe
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Dose Level 1
|
BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.
Inne nazwy:
Cisplatin is a chemotherapy drug
Inne nazwy:
IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells
Inne nazwy:
|
|
Eksperymentalny: Dose Level 2
|
BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.
Inne nazwy:
Cisplatin is a chemotherapy drug
Inne nazwy:
IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Maximum Tolerated Dose of Cisplatin
Ramy czasowe: While on treatment, up to 66 days
|
The trial uses 3+3 design to determine maximum tolerated dose (MTD). |
While on treatment, up to 66 days
|
|
Maximum Tolerated Dose of BKM120
Ramy czasowe: While on treatment, up to 66 days
|
The trial uses 3+3 design to determine maximum tolerated dose (MTD). |
While on treatment, up to 66 days
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Best Overall Response
Ramy czasowe: Measured at end of treatment, up to 66 days
|
The best overall response for each patient is given per Response Evaluation Criteria in Solid Tumors Criteria (RECIST 1.1) criteria: Complete Response (CR) - Disappearance of all target and non-target lesions and lymph node short axis is <10 mm and no new lesions Partial Response (PR)
Stable Disease (SD) - Less than 5 mm increase in target lesion diameter unless it results in a >=20% increase in diameter and >=1 persisting non-target lesion or tumor marker levels above normal limits and no new lesions Progressive Disease (PD)
|
Measured at end of treatment, up to 66 days
|
|
Median Time to Progression
Ramy czasowe: Up to 24 months (Progression is defined using RECIST v1.0 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions)
|
The median amount of time from baseline to progression and/or death. Patients known to be alive at last contact are censored at last contact. All patients alive at 24 months from baseline are censored at 24 months. |
Up to 24 months (Progression is defined using RECIST v1.0 as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions)
|
|
24 Month Overall Survival
Ramy czasowe: Up to 24 months
|
The probability of survival at 24 months using Kaplan-Meier estimates. Patients alive at 2 years are censored at 2 years. |
Up to 24 months
|
|
Median Anxiety Score Change
Ramy czasowe: From baseline to cycle 9, up to 66 days.
|
The median change in score on the Generalized Anxiety Disorder - 7 (GAD-7) questionnaire from baseline to cycle 9.GAD-7 has 7 questions and each question has score from 0 to 3. Sum score of all questions will be used as the final score. The final score ranges from 0 to 21. Higher score represents worse anxiety. |
From baseline to cycle 9, up to 66 days.
|
|
Median Depression Score Change
Ramy czasowe: From baseline to cycle 9, up to 66 days.
|
The median change in score on the Patient Health Questionnaire - 9 (PHQ-8) from baseline to cycle 9. PHQ-9 has 9 questions and each question has score from 0 to 3. Sum score of all questions will be used as the final score. The final score ranges from 0 to 27. Higher score represents worse depression. |
From baseline to cycle 9, up to 66 days.
|
|
P13K Status by Response
Ramy czasowe: Biopsies drawn up to 10 days from registration. Response measured at from baseline to cycle 9, up to 66 days.
|
Phosphoinositide 3-kinase (PI3K) biomarker status, either positive or negative, analyzed using established methods from tumor biopsies. P13K status is reported by response, either responder (CR or PR) or non-responder (SD or PR). |
Biopsies drawn up to 10 days from registration. Response measured at from baseline to cycle 9, up to 66 days.
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Robert Haddad, MD, Brigham and Women's Hospital
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Szacowany)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby Stomatognatyczne
- Nowotwory według lokalizacji
- Nowotwory
- Choroby Układu Oddechowego
- Nowotwory według typu histologicznego
- Nowotwory głowy i szyi
- Nowotwory gruczołowe i nabłonkowe
- Nowotwory Układu Oddechowego
- Rak
- Choroby otorynolaryngologiczne
- Nowotwory gardła
- Nowotwory otorynolaryngologiczne
- Choroby jamy nosowo-gardłowej
- Choroby gardła
- Rak, płaskonabłonkowy
- Choroby krtani
- Rak płaskonabłonkowy głowy i szyi
- Nowotwory jamy nosowo-gardłowej
- Nowotwory krtani
- Nowotwory gardła dolnego
- Lecznictwo
- Chemikalia nieorganiczne
- Związki chloru
- Związki azotu
- Związki platynowe
- Radioterapia
- Radioterapia, zgodna
- Radioterapia, wspomagana komputerowo
- Cisplatyna
- Radioterapia, modulowana intensywnością
- NVP-BKM120
Inne numery identyfikacyjne badania
- 14-008
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
There are no plans to share the IPD. Cumulative data will be published however.
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .